Abcam, ab185213, Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal CP2CJ antibody. C-terminal. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR6577,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, Flow Cyt (Intra), WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cytochrome p450 2C19 also known as CYP2C19 is a member of the cytochrome P450 superfamily of enzymes. It acts as a monooxygenase which means it catalyzes oxidation reactions in several substrates. The enzyme is approximately 55 kDa in mass and is mainly expressed in the liver. However it is also found in other tissues such as the intestines and brain. CYP2C19 plays a role in drug metabolism breaking down various endogenous and xenobiotic compounds.
Biological function summary
Cytochrome p450 2C19 contributes to the body's drug metabolism and detoxification processes. It is not part of any known enzymatic complex but plays a direct role in the metabolism of many clinically relevant drugs including proton pump inhibitors and antiplatelet medications. Through these actions the enzyme protects the body from potentially harmful effects of drugs and helps maintain metabolic homeostasis. This enzyme has genetic polymorphisms that lead to differences in drug metabolism among different individuals.
Pathways
The enzyme plays a significant role in the drug metabolism and pharmacokinetics pathways. CYP2C19 is involved in the hepatic phase I drug metabolism pathway where it metabolizes drugs into more polar excretable forms. It relates to other enzymes like CYP2C9 and CYP2D6 which together with it form the main subfamilies involved in the oxidation of a diverse range of lipophilic drugs and compounds. This allows for the extensive breakdown and unloading of various substances utilized in therapeutic contexts.
Cytochrome p450 2C19 variations can influence the metabolism of medications used in the treatment of cardiovascular diseases and depression. For example CYP2C19 polymorphisms affect the activation of the antiplatelet drug clopidogrel impacting patient outcomes in cardiovascular therapies. Additionally in psychiatric disorders variations in CYP2C19 can alter the effectiveness of selective serotonin reuptake inhibitors (SSRIs) which rely on the enzyme for their metabolism. It also links to CYP2C19's relationship with the CYP2C9 and CYP2D6 enzymes which share impact in drug efficacy and safety in different therapeutic areas.